Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411159 | 0.80 | NOS3 (0.48) | NOS3NOS2EHMT2ALOX15EHMT1 | |
| SCHEMBL12499637 | 0.73 | NOS3 (0.58) | NOS3NOS2EHMT2ALOX15EHMT1 | |
| SCHEMBL16608839 | 0.69 | LMNA (0.46) | ALDH1A1OGG1GAAMAPTL3MBTL1 | |
| SCHEMBL12411171 | 0.68 | GAA (0.46) | NOS3NOS2ALDH1A1GAA | |
| SCHEMBL25166554 | 0.66 | NOS3 (0.48) | NOS3NOS2ALOX15ALDH1A1GAA | |
| SCHEMBL13437804 | 0.65 | NOS3 (0.52) | NOS3NOS2ALOX15ALDH1A1MAPT | |
| SCHEMBL4915813 | 0.63 | NOS3 (0.60) | NOS3NOS2ALOX15ALDH1A1GAA | |
| SCHEMBL12410776 | 0.63 | LMNA (0.52) | ALDH1A1GAAMAPTL3MBTL1 | |
| SCHEMBL19477060 | 0.63 | EHMT2 (0.65) | EHMT2EHMT1DOT1L | |
| SCHEMBL25166016 | 0.63 | ALDH1A1 (0.33) | NOS3NOS2EHMT2EHMT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | NOS3 1274/4885NOS2 1177/4885EHMT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.